PI3K inhibition combined with anti-PD-1 and anti-CTLA-4 significantly inhibited tumour growth and increased durable DC, NK cell and CD8+ T-cell responses compared to ICB alone in mouse models of this carcinoma subtype [221]. Here, PDCD1 is linked to neoplasm.